Phosphine Silane

Summary

Phosphine Silane (CHEMBL6068763) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 96.08 Da · H6P2Si

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068763
Name	Phosphine Silane
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	172789886
Molecular formula	H6P2Si
Molecular weight	96.08
InChIKey	MEKVANUCYRDQPE-UHFFFAOYSA-N

SMILES: [Si].P.P

Parent form; salt/anhydrous children: CHEMBL6067999

Patent coverage: 8 distinct patent families (11 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).